Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study
Primary result · Urinary TXMResult — go to the resultReduction 20% 95% CI 5-31 %Authors' conclusion
Very-low-dose rivaroxaban and low-dose aspirin in T2DM patients significantly inhibit in vivo platelet function, TG and isoprostane formation.
Study context
- Population
- T2D patients with stable atherothrombotic disease on low-dose aspirin; 12 females, aged 69 [65–72]73 analysed
- Participants
- 75 patients
- Comparison
- Low-dose rivaroxaban plus aspirin vs aspirin alone
- Primary endpoint
- In vivo platelet activation by urinary thromboxane A2 metabolite (TXM)
Methodological detailsopen-label, No carryover effects were observed
- Open-label
- No carryover effects were observed
Primary result
Urinary TXM
Reduction
20%
95% CI 5-31 %
P < 0.01
As reported in the abstract
Further findings
| Outcome | Reduction (CI) | P value |
|---|---|---|
| Urinary isoprostanen = 73 | 19% (12–26%) | P < 0.01 |
Thrombin generation (TG) velocity index and peak at rivaroxaban's maximal concentration
- TG velocity index reduction vs aspirin alone
- 44% [37-52%]
- TG peak reduction vs aspirin alone
- 81%[75-87%]
Inflammation and endothelial biomarkers
- Inflammation and endothelial biomarkers were unchanged
Original publication
Effects of low-dose rivaroxaban combined with low-dose aspirin versus low-dose aspirin alone on in vivo platelet activation, endothelial function and inflammation in type 2 diabetes patients with stable atherosclerotic disease: the RivAsa randomized, crossover study. Diabetes Res Clin Pract. Published 9 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →